Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
Facts & Figures News Career Baxter Worldwide
 


  Milestones


  • 2004 Baxter receives European Commission Marketing Authorization for ADVATE


  • 2003 Baxter announced that the U.S. Food and Drug Administration (FDA) approved ADVATE for the prevention and control of bleeding episodes in people with hemophilia A.


  • 2003 Baxter awarded a $10 million contract by the National Institute of Allergy and Infectious Diseases (NIAID) to develop and produce an inactivated coronavirus vaccine against Severe Acute Respiratory Syndrome (SARS) for use by the National Institutes of Health (NIH) in phase I/II clinical trials.


  • 2002 Baxter receives regulatory approval in the Netherlands for INFLUJECT, the company’s novel new influenza vaccine.


  • 2001 Baxter announced that it would participate in the production of approximately 155 million doses of smallpox vaccine for the United States government, in conjunction with Acambis Inc.


  • 2001 Baxter, Hyland Immuno changes name to Baxter BioScience.


  • 2001 Baxter announces the $170 million investment into a state-of-the-art cell culture facility.


  • 2000 Baxter launches its group C meningococcal conjugate vaccine NeisVac-C in the UK.


  • 2000 Baxter forms strategic alliance with Acambis.


  • 2000 Baxter acquires North American Vaccine, Inc.


  • 2000 Hyland Immuno begins clinical trials of the first protein-free manufactured FVIII.


  • 1999 Tisseel launched in US - first fibrin sealant approved by the US FDA.


  • 1996 Baxter acquires Immuno AG; new entity called Baxter Hyland Immuno.


  • 1992 Hyland markets the first genetically engineered FVIII concentrate.


  • 1988 Hyland produces the first plasma derived FVIII that is virally inactivated by a solvent/detergent treatment and purified by monoclonal antibody technology.


  • 1987 Hyland begins the first human clinical trials of a recombinant FVIII concentrate.


  • 1984 Baxter develops the artificial heart "Novacor".


  • 1983 Immuno opens its Biomedical Research Center in Austria.


  • 1979 Hyland introduces the first anti-inhibitor coagulant complex.


  • 1976 Immuno produces Tisseel fibrin sealant.


  • 1975 Immuno starts production of TBE vaccine.


  • 1970 Immuno develops coagulation factor concentrate.


  • 1966 Hyland develops the first commercially available FVIII concentrate.


  • 1963 Immuno develops tetanus immunoglobulin.


  • 1956 Immuno co-develops polio vaccine.


  • 1956 Baxter develops the first artificially manufactured kidney.


  • 1954 Immuno launches Albumin and antihemophilic solutions.


  • 1953 Immuno AG founded in Austria.


  • 1952 Baxter acquires Hyland Laboratories.


  • 1941 Hyland Laboratories first company to produce and distribute plasma.



 » Printversion

 
 
  » find


 

Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-based Pandemic Flu Vaccine
» read more

The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
» read more

U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSC´s DVC and Baxter
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,